We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Blood-Based ctDNA Test Demonstrates Acceptable Accuracy for Colorectal Cancer Detection

By LabMedica International staff writers
Posted on 09 Jun 2025

Colorectal cancer (CRC) remains the second leading cause of cancer-related deaths globally, with over 1. More...

9 million new cases and 930,000 deaths reported in 2020 alone. Early detection through regular screening is crucial for reducing both incidence and mortality. While current methods like stool-based tests and visual exams are widely used, there is growing interest in blood-based tests as a less invasive alternative. A prospective study published in JAMA highlights a new blood-based circulating tumor DNA (ctDNA) test that demonstrated 79.2% sensitivity and 91.5% specificity for CRC detection, suggesting it could serve as a viable noninvasive screening tool.

The population-based, observational study by researchers from NYU Grossman School of Medicine (New York, NY, USA) aimed to evaluate the diagnostic accuracy of this investigational test in a large, average-risk screening population. It was conducted between May 2020 and April 2022 across 201 centers in the United States and the United Arab Emirates. All participants were asymptomatic adults aged 45 to 85 years and considered to be at average risk for CRC. The study was conducted under blinded conditions, with both participants and study personnel unaware of the test results, to minimize potential bias. Participants underwent a blood draw followed by a standard-of-care colonoscopy. Blood samples were collected either on-site or through mobile phlebotomy. The ctDNA test is designed to detect mutations linked to colorectal cancer in the bloodstream. The study’s primary outcomes were sensitivity for CRC, specificity for advanced colorectal neoplasia, and both positive and negative predictive values. Sensitivity for detecting advanced precancerous lesions was assessed as a secondary endpoint.

Among 27,010 participants in the evaluable cohort, with a mean age of 58.1 years and 55.8% identifying as women, the blood-based test met all prespecified criteria for its primary endpoints. It showed 79.2% sensitivity for CRC detection and 91.5% specificity for advanced colorectal neoplasia. The test achieved a negative predictive value of 90.8% and a positive predictive value of 15.5%. However, its sensitivity for detecting advanced precancerous lesions was 12.5%, which did not meet the predefined threshold. The researchers acknowledged certain limitations. The study only assessed the one-time diagnostic accuracy of the blood-based test and did not compare it with other existing screening methods in terms of patient acceptability or long-term effectiveness. Additionally, the impact of such blood-based testing on CRC incidence and mortality, as well as the ideal screening interval, remains uncertain and will require further exploration through future studies and modeling. Despite these constraints, the study was strengthened by its large and demographically diverse sample drawn from urban and rural regions in the US. The use of a decentralized trial platform, which allowed for both direct-to-participant and site-based enrollment, was instrumental in maintaining enrollment momentum during the COVID-19 pandemic and reaching underrepresented areas.

“In an average-risk colorectal cancer screening population, a blood-based test demonstrated acceptable accuracy for [CRC] detection, but detection of advanced precancerous lesions remains a challenge, and ongoing efforts are needed to improve test sensitivity,” wrote the researchers.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
C-Reactive Protein Rapid Test
Afinion CRP
New
Urine Drug Test
Instant-view® Phencyclidine Urine Drug Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more

Industry

view channel
Image: The knowledge transfer partnership will further develop technology to rapidly diagnose serious and high-risk infectious diseases (Photo courtesy of Aston University)

Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. A Knowledge Transfer Partnership (KTP)... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.